Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM)

Maria Antonietta Gambacorta, Giovanni Capelli, Idor De Simone, Domenico Cristiano Corsi, Sergio Guido Luppi, Attilio Restivo, Giulia Capelli, Irene De Simone, Gaya Spolverato, Michela Cinquini, Ivan Moschetti, Sara Lonardi, Gianluca Masi, Chiara Carlomagno, Gabriele Luppi, Francesca Valvo, Renato Cannizzaro, Federica Grillo, Angelo Restivo, Marco MessinaAlessandro Pastorino, Carlo Aschele, Salvatore Pucciarelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: The standard approach for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). After nCRT 20% of patients achieve a clinical complete response (pCR) and could be treated with a non-operative management (NOM). Methods: The panel of the Italian Association of Medical Oncology (AIOM) Guidelines on rectal cancer applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach addressing the following question: Should NOM vs. TME be used for patients with rectal cancer with clinical complete response after nCRT? Five outcomes were identified: disease-free survival (DFS), mortality, local recurrence, colostomy rate, and functional outcomes. Results: Nine studies were included in the analysis. A higher risk of disease recurrence was observed in the NOM group compared to the TME group (RR = 1.69, 95% CI 1.08, 2.64) on the other hand, we observed a slightly positive but not significant effect on mortality of NOM (RR = 0.82, 95% CI 0.46, 1.45). Patients in the NOM group were more likely to experience local recurrence (RR = 5.37, 95% CI 2.56, 11.27) and patients in the TME group were more likely to have a permanent colostomy (RR = 0.15, 95% CI 0.08, 0.29). Only one study evaluated functional outcomes. The overall certainty of evidence was rated as very low. Conclusions: NOM was found to correlate with a higher risk of local recurrence which did not translate in worse OS and a lower colostomy rate. Due to the paucity of evidences, no recommendations are possible. NOM remains an experimental treatment; thus, patients managed with NOM should be enrolled in clinical trials with a dedicated follow-up schedule.
Lingua originaleEnglish
pagine (da-a)2150-2159
Numero di pagine10
RivistaJournal of Gastrointestinal Surgery
Volume24
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • GRADE
  • Rectal Neoplasms
  • Neoadjuvant chemotherapy
  • Rectal cancer
  • Surgery
  • Antineoplastic Combined Chemotherapy Protocols
  • Chemoradiotherapy
  • Disease-Free Survival
  • GRADE Approach
  • Humans
  • Italy
  • Medical Oncology
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Treatment Outcome
  • Writing
  • Neoadjuvant Therapy
  • Metanalysis

Fingerprint

Entra nei temi di ricerca di 'Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM)'. Insieme formano una fingerprint unica.

Cita questo